Eye News and Research

Latest Eye News and Research

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species -- mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103.

14 Oct 2009

Harvard researchers unite in fight against antibiotic resistance

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) have awarded $5 million to an interdisciplinary group of Harvard researchers to launch the "Harvard-wide Program on Antibiotic Resistance."

14 Oct 2009

International Stem Cell launches human cell culture products into commercial research markets

International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs.

14 Oct 2009

New UCL cancer research centre launched in UK

A new centre is launched in London today (Wednesday), joining a select group of Cancer Research UK Centres across the UK.

14 Oct 2009

States eye budget cuts and health reform

Pennsylvania's hospitals got a small piece of good news when an overdue budget came with smaller than expected cuts. But there and in other states, programs continue to find programs and budgets on the chopping block.

14 Oct 2009

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.

14 Oct 2009

Clinical trial results of the LensAR Laser System to be presented at the 2009 AAO and PAAO joint meeting

LensAR, Inc., a leading developer of next generation laser technology for cataract surgery and other ocular applications, today announced that data from a recently completed clinical trial of the LensAR Laser System will be presented at the upcoming 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and Pan-American Academy of Ophthalmology (PAAO). The meeting will be held October 23 - 27, 2009 in San Francisco, CA.

13 Oct 2009

OBP Medical launches cost effective, patient friendly disposable briefs

While walking the road to recovery a patient should at all times feel secure and comfortable in the attire provided to them by their healthcare facility. Here to help is OBP Medical Inc.'s Under Johnnies(TM) Brief with Pad: a cost effective, patient friendly, line of disposable briefs with ultra absorbent padding for patients with post operative bleeding or discharge.

13 Oct 2009

Increasing number of pre-term infants experience eye disorders

As more extremely pre-term infants survive in Sweden, an increasing number of babies are experiencing vision problems caused by abnormalities involving the retina, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

13 Oct 2009

Surgeons perform groundbreaking procedure using patient's own stem cells for repairing bone deficiencies

In a first-of-its kind procedure, physicians have used stem cells taken from the fat tissue of a 14-year-old boy and combined them with growth protein and donor tissue to grow viable cheek bones in the teen.

13 Oct 2009

Report shows that visual impairments are associated with the risk of death in older adults

Visual problems that cannot be corrected are associated with increased risk of death among individuals between the ages of 49 and 74, and all visual impairments may be associated with the risk of death in older adults, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

13 Oct 2009

The Hallowell Centers include beneficial exercises in treatment of ADHD

New brain research is unlocking long-standing mysteries, explaining how the brain trains itself and how human beings develop their superior cognitive skills. New scanning tools (FMRI, SPECT, QEEG, etc.) are advancing neurology's understanding of a process called neuroplasticity and shedding light on a simple looking balance and movement regimen used since 1982 by developmental specialists to treat people with ADHD, Dyslexia and other learning differences.

12 Oct 2009

Common myths about children's eye health and the medical reality behind them

Many parents grew up with medical adages or advice that have since been proven by scientists to be incorrect or outdated. Here are five common myths about children's eye health and the medical reality behind them, prepared by the physicians at The Vision Center at Childrens Hospital Los Angeles.

12 Oct 2009

PFCD releases the updated comparison of chronic care provisions contained within health reform bill

The Partnership to Fight Chronic Disease (PFCD) today released an updated comparison of chronic care provisions contained within health reform legislation to reflect the amended Senate Finance Committee proposal. The amended "Chairman's Mark" includes numerous provisions to prevent and manage chronic disease, the top cost driver in health care, as do the two other major pieces of health reform legislation under consideration in Congress.

9 Oct 2009

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

9 Oct 2009

Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients

Lpath, Inc., the category leader in lipidomics-based therapeutics, reported positive summary results of its single-dose Phase 1 clinical trial of iSONEP™ in wet-AMD patients.

8 Oct 2009

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

Valensa International (Orlando, FL USA) announced today that it has initiated a broad out licensing effort for University of Illinois patent (US 5,527,533 and its foreign equivalents) for the use of the astaxanthin in eye healthcare dietary supplement applications.

8 Oct 2009

Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration

MacuCLEAR, Inc. and Mystic Pharmaceuticals, Inc., announced today preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD). The preliminary results indicated that MacuCLEAR’s MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina.

8 Oct 2009

Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital.

8 Oct 2009

Lions Eye Institute for Transplant & Research to study vision impairment and blindness

Real-time biomedical studies of factors leading to vision impairment are now possible through the world's largest ocular research center at Lions Eye Institute for Transplant & Research.

8 Oct 2009

Eye News and Research

Latest Eye News and Research

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Harvard researchers unite in fight against antibiotic resistance

International Stem Cell launches human cell culture products into commercial research markets

New UCL cancer research centre launched in UK

States eye budget cuts and health reform

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

Clinical trial results of the LensAR Laser System to be presented at the 2009 AAO and PAAO joint meeting

OBP Medical launches cost effective, patient friendly disposable briefs

Increasing number of pre-term infants experience eye disorders

Surgeons perform groundbreaking procedure using patient's own stem cells for repairing bone deficiencies

Report shows that visual impairments are associated with the risk of death in older adults

The Hallowell Centers include beneficial exercises in treatment of ADHD

Common myths about children's eye health and the medical reality behind them

PFCD releases the updated comparison of chronic care provisions contained within health reform bill

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration

Mimetogen Pharmaceuticals completes its equity financing

Lions Eye Institute for Transplant & Research to study vision impairment and blindness

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Eye News and Research

Latest Eye News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in